Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2005

View Archived Issues

BRL-52537, a kappa opioid receptor agonist, provides ischemic neuroprotection in males only

PARP inhibitor shows neuroprotective effects in preclinical models of ischemia

Novel ependymin-like peptides are neuroprotective in preclinical stroke model

Pfizer inlicenses Schering's ADP receptor antagonist program

Nascobal Nasal Spray receives FDA approval

Pfizer refutes Public Citizen claims on Celebrex study

IND granted for ALS-357

PT-523 studied for NSCLC in phase I/II trial

Phase II study of REN-1654 for postherpetic neuralgia completes recruitment

Safety milestone met in phase I/II bone grafting study of Tissue Repair Cells

GTx initiates phase I trial for ostarine

ODAC to review Combidex regulatory filing in March

ComGenex transfers to Echelon rights to PI3K inhibitors from joint program

Valeant to acquire Xcel Pharmaceuticals

Curis to codevelop basal cell carcinoma drug candidate with Genentech

Schwarz resubmits NDA for rotigotine

Phase III confirmatory study of Photrex planned

NovoLog Mix 70/30 reported effective as initiating insulin therapy for type 2 diabetes

Preclinical evidence for the potential benefits of sildenafil in cystic fibrosis

KRP-203 increases allograft survival in rat models of chronic rejection

Pegasys receives European approval for HIV-HCV coinfected patients

Low adiponectin levels increase the risk of CAD in type 1 diabetes

RXR-selective agonist 9c-UAB-30 prevents breast cancer without any toxicity

Pokemon: a potential new target for development of anticancer drugs

Schering claims use of Rho-kinase inhibitors for cardiac hypertrophy and aneurysm

New varenicline formulations for smoking cessation reported by Pfizer

Ranbaxy prepares novel formulations of antibiotic cefpodoxime with improved bioavailability

Novel ACE inhibitors emerge from NicOx R&D

HER2 inhibitors developed at Pfizer

HMG-CoA reductase inhibitors identified by Ranbaxy team

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...